Immunic Enhances Biotechnology Presence with Innovative Therapies at Key Conferences

Immunic Strengthens Presence in Biotechnology Conferences to Showcase Innovative Therapies

Immunic, Inc., a biotechnology firm specializing in small molecule therapies for chronic inflammatory and autoimmune diseases, actively engages in the biotechnology sector by participating in key industry conferences in November 2025. The company's leadership team, including CEO Daniel Vitt, CSO Hella Kohlhof, and VP of Investor Relations Jessica Breu, attends the BIO-Europe conference in Vienna from November 3-5. This event provides a platform for networking and potential partnerships, allowing Immunic to strengthen collaborations that could further its mission of advancing innovative treatments. Parties interested in connecting with Immunic executives can schedule meetings through the BIO-Europe partneringONE portal or by directly contacting Jessica Breu.

Following the BIO-Europe conference, Dr. Vitt and COO Jason Tardio will conduct one-on-one meetings at the Jefferies Global Healthcare Conference in London on November 19-20. This two-pronged outreach strategy highlights Immunic's commitment to fostering relationships within the healthcare community while showcasing its promising therapeutic developments. The company emphasizes its lead program, vidofludimus calcium (IMU-838), which is currently undergoing phase 3 trials for relapsing multiple sclerosis. The anticipated top-line data from these trials is expected by the end of 2026, underscoring the urgency and significance of Immunic's ongoing research efforts.

Vidofludimus calcium stands out as a first-in-class nuclear receptor-related 1 (Nurr1) activator, providing neuroprotective effects while also inhibiting dihydroorotate dehydrogenase (DHODH) to exert anti-inflammatory and antiviral effects. The drug has shown promising results in phase 2 trials for both relapsing-remitting and progressive forms of multiple sclerosis, contributing to the growing body of evidence supporting its efficacy. In addition to IMU-838, Immunic is also focused on the development of IMU-856, which targets Sirtuin 6 (SIRT6) to enhance intestinal barrier function, with implications for conditions like celiac disease and inflammatory bowel disease. Furthermore, the company is advancing IMU-381, a next-generation therapy for gastrointestinal diseases, which is currently in preclinical testing.

In summary, Immunic's participation in the upcoming conferences highlights its proactive approach to engaging with potential partners in the biotechnology sector. As it advances its innovative therapies aimed at addressing chronic inflammatory and autoimmune conditions, Immunic positions itself as a key player in the ongoing evolution of treatment options in this critical area of healthcare. For further details on its initiatives and programs, interested individuals can access more information at www.imux.com.